Implications for Practice
DISEASE, SOLID TUMORS
This first-in-human study demonstrated that senaparib was well tolerated in patients with advanced solid tumors. Moreover, there were encouraging signs of antitumor efficacy and disease control; 10 of the 44 evaluable patients achieved a partial response and another 18 had stable disease. Patients harboring 